Should I buy Genpact (G) stock or is it too late?

Genpact · Industrials · price $35

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Susquehanna — 63% of its targets hit on this sector (67 calls tested). It aims for $37 (+5.1 %), call made on August 8, 2026, maturing on August 8, 2027 (67 d ago).

The 5 reliable analysts $43+22 %

The 2 other firms $38.50+9.3 %

How to read it: the 5 reliable firms are not filtered by optimism — 5 aim above the price, 0 below, hence their $43 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Genpact

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Needham	45 %	+8.1 %	20	$45 +28%
Citigroup	58 %	+6.3 %	12	$36 +2%
JP Morgan	33 %	-7.8 %	9	$45 +28%

In short — Should you invest in Genpact? Is it too late, still worth it? Analysts are split (29% buy, median target $39, i.e. +11%), and the most reliable on G targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $39, i.e. +11% from the current price ($35).
The most reliable firm on G, Citigroup (58% hit rate, 12 scored calls), targets $36 (call made on August 7, 2026, maturing on August 7, 2027) (+2%) in its most recent call, and $43 (call made on October 23, 2025, maturing on October 23, 2026) (+22%) in the one coming due soonest.
Pays a dividend (1.9% yield) — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 5 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on G

Median target $39 (+11%) · 7 ratings · Hold consensus

Strong Buy00%

Buy229%

Hold571%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Genpact now?

We won't decide for you. The facts: 29% of analysts rate it a buy, median target $39 (+11%), and Citigroup (most reliable on G, 58%) targets $36. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Genpact?

Not according to analysts: the median target ($39) is still +11% above the current price ($35) (most reliable on G: Citigroup, 58%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Genpact still worth investing in?

It depends on the gap between the price ($35) and its estimated value: analysts target $39 on median (+11%), with 29% buys (most reliable on G: Citigroup, 58%). Cross-check with their real reliability on G and the cautions above. Information, not advice.

What's the main risk in buying G?

The consensus is not unanimous: of 7 ratings, 5 are neutral.

→ Go deeper: the full Genpact profile (consensus, analyst reliability, price target, performance).